Business Insights Report “The Dermatology Market Outlook to 2016” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/26/2011 -- This report covers the global dermatology market. The key dermatological indications are profiled in the report and the epidemiology of each of these indications is analysed and forecast to 2016. Leading products in each indication are identified, including those in the pipeline and their sales forecast to 2016. The leading players are profiled and their dermatology revenues forecast to 2016.

Features and benefits
* Analyse the epidemiology of key dermatological indications including acne, psoriasis, dermatitis, rosacea, and skin infections with forecasts to 2016.
* Understand the makeup of the dermatology market in terms of revenues by disease area and individual drugs.
* Forecast the future of the dermatology market with this report's forecasts of sales and epidemiology.
* Understand the future of leading players including Galderma, GSK, Nycomed US, Astellas, and Leo Pharma.
* Analyze the dermatology product pipeline and assess which products have the greatest market potential.

Highlights
Although psoriasis has the smallest patient population of the dermatological indications studied in the report (18 million globally) it has the fastest growing sales and represents almost a fifth of the market. This is indicative of the relative seriousness of the condition and high treatment rates.

Combination products are expected to drive the growth of the anti-acne market segment. The most successful combination products in this market segment are Duac by GSK/Stiefel, BenzaClin by Sanofi, and Ziana by Medicis.

Leo Pharma had dermatology sales of $1.3bn in 2010 which was a near 20% increase on 2009. This increase was largely a result of the reacquisition of the US rights to its products from Watson. Future growth for the company is expected be driven by its pipeline actinic keratosis treatment ingenol mebutate.

Your key questions answered
* Which of the disease areas in the dermatology market have the greatest patient potential through to 2016?
* How big is the dermatology market and which dermatological conditions are the largest opportunities in terms of sales?
* What are the key innovative products that will drive growth in the dermatology market?
* How will the introduction of innovative products impact incumbent products and players?
* What are the strategies of the leading players in this market and how are they forecast to perform through to 2016?

Buy Now: http://www.reportsnreports.com/reports/109468-the-dermatology-market-outlook-to-2016.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Infiniti Research’s Report “RFID in Healthcare Industry 2010-2014” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/25/2011 -- TechNavio's analysts forecast the RFID market in the Healthcare industry to grow at a CAGR of 29 percent over the period of 2010–2014. One of the key factors contributing to this market growth is the reduced cost of RFID tags. The RFID market in the Healthcare industry has also been witnessing vendors entering into strategic alliances and partnerships.

However, security issues regarding inventory could pose a challenge to the growth of this market.

Key vendors dominating this market space include Motorola Solutions, Alien Technology, IBM, Intermec, Inc., and Impinj.

TechNavio's RFID in Healthcare Industry 2010–2014 report has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on the Americas, the EMEA, and the APAC regions; it covers the growth of the RFID market in the Healthcare industry and the major vendors that provide RFID products and services in the Global Healthcare market.

Key questions answered in this report:
• What will the market size be in 2014 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

Buy Now: http://www.reportsnreports.com/reports/103554-rfid-in-healthcare-industry-2010-2014.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

IMARC Group’s Report “Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/18/2011 -- Driven by a strong growth in the sales of temperature sensitive healthcare products, the demand for cold chain logistic services is currently experiencing explosive growth. IMARC Group, one of the world's leading research and advisory firms, finds that the total size of the healthcare cold chain logistic services market is expected to expand from its current figures of US$ 6.1 billion to nearly US$ 9.5 billion by 2016.

IMARC's new report entitled "Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)" provides an analytical and statistical insight into the logistic opportunities in the global healthcare market. The study that has been undertaken using both desk based as well as qualitative primary market research has analyzed three aspects of the global healthcare cold chain logistics market.

What we have achieved in this report:
Comprehensive Market Analysis of Temperature Sensitive Healthcare Products:
Classes Covered: Biopharmaceuticals, Vaccines & Clinical Trial Materials

Focus of the Analysis in Each Class:
• Drivers and challenges
• Historical sales trends
• Logistic requirements
• Impact of temperature excursions
• Opportunities in cold chain services
• Market outlook (2011-2016)

Understanding the Operations of a Healthcare Cold Chain Distribution Process
Focus of the Analysis:
• Understanding the various methods of cold chain distribution and their advantages/disadvantages
• Understanding the cold chain requirements for various temperature sensitive healthcare products and the impact of temperature excursions
• Understanding the various costs involved in cold chain transportation and comparing it with non-cold chain transportation
• Understanding the key steps required in the setting and organization of an efficient cold chain distribution process
Comprehensive Market Analysis of the Healthcare Cold Chain Logistic Services Market

Focus of the analysis:
• Quantifying the global healthcare cold chain logistic services market
• Quantifying the market size by product
• Quantifying the market size by service
• Quantifying the market size by region

Information Sources:
Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

Buy Now: http://www.reportsnreports.com/reports/98636-global-healthcare-cold-chain-logistics-market-report-forecast-.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights Report “Developments in Neurostimulation” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/12/2011 -- The magnitude of research and development executed in neurostimulation innovation is high. Some of the prominent areas in neurostimulation where extensive clinical trails are executed include deep brain stimulation (DBS), spinal cord stimulation (SCS), and microstimulation.

Features and benefits
• Identify the specific diseases for which neurostimulation has potential applicability.
• Understand the scientific principles underlying neurostimulation technologies, and how the devices differ between disease areas.
• Assess the areas in which further research is necessary before neurostimulation devices become widespread clinical tools.
• Examine the most prominent challenges remaining to be solved and analyze the hurdles that have slowed progress.
• Gain an overview of key companies in the field and compare their level of research activity and areas of research focus.

Highlights
The microstimulator was proposed to be a single point solution, being capable of treating all neurological pathologies. The Bion microstimulator has shown considerable promise, but since its aquisition by Boston Scientific, progress to the market has slowed dramatically.

Progress in the development of devices for drop foot and grasp is limited by two main challenges. The first is the need for placing electrodes at more than one location, because muscles work in groups. The second is battery life, owing to the high current needed to stimulate the large muscles, and the highly variable patient to patient usage.

Deep brain stimulation has shown promise for the treatment of both depression and obsessive-compulsive disorder, although such use remains at a nascent stage and larger scale trials will be necessary to provide conclusive evidence.

Your key questions answered
• What are the prominent neurological pathologies that are the subject of research into treatment by the application of neurostimulation devices?
• How will neurostimulation devices evolve over the next decade?
• What research challenges prevail in the application of neurostimulation devices?
• What key neurostimulation patent applications have been published recently?
• How successful is transcranial magnetic stimulation in treatment of depression?

Buy Now: http://www.reportsnreports.com/reports/94865-developments-in-neurostimulation.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “GlaxoSmithKline plc: PharmaVitae Profile” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/11/2011 -- This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
• Gain insight into GlaxoSmithKline's strategic outlook across the next 6 years.
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights
Strategic insight into the prospects for GlaxoSmithKline over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
• Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical sector
• Assess GlaxoSmithKline's continued diversification strategy with vaccines and emerging markets positioned as key growth opportunities.
• Analyse how life-cycle managment (and a lack of generic competition) will facilitate GSK's continued strong position in the global asthma/COPD market.

Buy Now: http://www.reportsnreports.com/reports/7806-glaxosmithkline-plc-pharmavitae-profile.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “Genzyme Corporation” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/08/2011 -- This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
• Gain insight into Genzyme's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights
Strategic insight into the prospects for Genzyme over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
• Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
• Assess the impact of the Allston Landing contamination issues to the company's top line sales performance
• Understand the level of sales growth and portfolio diversification Genzyme will offer Sanofi-Aventis, post acquisition

Buy Now: http://www.reportsnreports.com/reports/83956-genzyme-corporation.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “AstraZeneca: PharmaVitae Profile” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/07/2011 -- This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Buy Now: http://www.reportsnreports.com/reports/83955-astrazeneca-pharmavitae-profile.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

Features and benefits

• Gain insight into AstraZeneca's strategic outlook across the next 6 years

• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for AstraZeneca over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

• Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector

• Assess the importance of Crestor, set to become the industry's biggest-selling product, to AstraZeneca's forecast growth performance

• Analyse AstraZeneca's high level of anticipated exposure to flagship product patent expiries through to 2015 and the impact on company strategy

About Us
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights Report “Optimizing clinical trials through IT” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/06/2011 -- A wide variety of information technologies are now employed in support of clinical trials. Pharma companies are beginning to take a more holistic view and seek to integrate their management and oversight of the trial. This report examines how industry trends are shaping these technologies, and how they can be optimally applied to improve, quality, safety and efficiency in clinical trials.

Features and benefits
• Examine the trends shaping clinical trials.
• Learn how social media are being used in patient recruitment.
• Analyse the potential of electronic health record data in clinical development.
• Review the ways in which cloud computing is changing clinical trials.
• Understand the future of information technology use in clinical trials.

Highlights
The EDC market is forecast to grow at a CAGR of 13%, reaching $1.2bn in 2016. EDC will be employed in smaller studies as services become commoditized and set-up times and costs reduce. The key trend within EDC is the move towards an integrated eClinical approach in which data from multiple sources is integrated in a hub arrangement.

The majority of trial sites do not meet their enrolment targets. To address this, a variety of sources of data can be used to optimize patient recruitment through better protocol design, site selection and patient identification. Site performance data, electronic patient records, and health information networks are the key sources.

Cloud architecture will gain penetration, which will reduce the demand for internal IT resource. In parallel, patients, site staff and trial managers will access trial software using wide range of channels and devices. Pharma sponsors will take an increasingly holistic view, enmeshing their information strategies with wider organizational goals.

Your key questions answered
• How can data integration be achieved, and what benefits does this offer?
• In what ways are electronic health records being used to improve clinical trials?
• How can technologies be optimally integrated in clinical trials?
• How will the EDC market change to 2016?
• How can social media be used to improve patient recruitment?

Buy Now: http://www.reportsnreports.com/reports/90238-optimizing-clinical-trials-through-it.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights Report “The Cancer Market Outlook to 2016” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/05/2011 -- The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.

Features and benefits
• Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes.
• Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change.
• Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D.
• Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products.
• Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.

Highlights
The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.
Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.
Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.

Your key questions answered
• What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
• Which were the leading players in the cancer market in 2010?
• Which products will be the future growth drivers for the cancer health market?
• Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?
• Which companies are best positioned to succeed in the cancer market over the period 2010–16?

Buy Now: http://www.reportsnreports.com/reports/90235-the-cancer-market-outlook-to-2016.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights Report “The Stem Cell Market Outlook” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/05/2011 -- This report covers the commercialization of stem cells (primarily derived from adult tissues) which are transplanted into patients to improve the function of diseased/damaged tissues/organs. Six indications are covered in detail. Sales forecasts are estimated in the US and five major European markets (5EU), which include France, Germany, Italy, Spain and the UK.

Features and benefits
• Identify potential growth markets with sales forecasts by indication and expected timing of market entry.
• Compare the different business models for stem cell therapies.
• Evaluate which novel products offer the greatest potential clinical advances over the next several years and why.
• Assess potential clinical advances and how they address current unmet needs.
• Understand the drivers and resistors of the stem cell market.

Highlights
Six indications were prioritized based on likely commercial potential and adoption into clinical practice: acute myocardial infarction, heart failure, critical limb ischemia, amyotrophic lateral sclerosis, spinal cord injury and ischemic stroke.

Companies are developing first generation therapies primarily based on ex vivo expanded allogeneic or autologous bone marrow derived stem cells. Recently, a second generation of products has entered clinical development, which may build on the efficacy of first generation products.

The greatest potential revenues are forecast in diseases or conditions with significant mortality or morbidity and limited treatment options, for which autologous bone marrow mononuclear cells (BMMNCs) may not be applicable or ineffective and lower patient numbers can be offset by higher prices.

Your key questions answered
• What is the future commercial value of stem cell therapies?
• Which products are likely to be reimbursed and what price could be charged?
• Which indications offer the greatest sales potential?
• What are the competitive risks to commercialization and how can companies develop profitable business models?
• Which companies are attractive for investment?

Buy Now: http://www.reportsnreports.com/reports/90237-the-stem-cell-market-outlook.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MarketsandMarkets Report “Healthcare IT Market in Emerging Economies (2010 - 2015)” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/01/2011 -- The growth of medical tourism, demand for better quality healthcare delivery by growing aging population, and increase in chronic disease patient population is driving the increased adoption of IT solutions in the emerging markets. The Healthcare IT markets in emerging economies is expected to grow from $5.3 billion in 2010 to $10.9 billion in 2015, at an estimated CAGR of 15.3% from 2010 to 2015. The hardware segment dominates the healthcare IT market in emerging economies and is expected to be the fastest growing segment for the next 5-7 years.

IT solutions such as clinical information systems and administrative/non-clinical systems are mostly used in private sector hospitals in the developing countries. Most hospitals in these countries are equipped with basic administrative systems for billing and patient scheduling. However, there will be a gradual increase in the use of clinical information systems such as EMR, PACS, LIS, RIS etc. once the IT infrastructure has been developed.

What makes our reports unique?
We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Buy Now: http://www.reportsnreports.com/reports/75620-healthcare-it-market-in-emerging-economies-2010-2015.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “R&D Trends: Obesity - 2006–2011: obesity’s lean years” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/30/2011 -- Modest efficacy results and lingering safety concerns have meant that developers of obesity drugs have failed to convince regulators of their risk-benefit profiles. The continued escalation of safety requirements in the light of recent withdrawals might see another raft of discontinuations, as Datamonitor views the chances of the late-stage pipeline candidates expanding the obesity market as slim

Features and benefits
• Analyze the current obesity pipeline and identify trends that will shape its future
• Establish the minimum acceptable and target product profiles necessary for success in the obesity market
• Assess the challenges faced in treating obesity and the future direction for obesity therapy
• Provide insight into clinical trial design in obesity

Highlights
With no new approvals since rimonabant in 2006 and after the 2010 market withdrawal of sibutramine there is now only one prescription drug, Xenical (orlistat; Roche), approved for the long-term management of obesity in the US, France, Germany, Italy, Spain, and the UK. Of the five drugs that were in Phase III in 2009, all remain in development
Three Complete Response Letters issued by the FDA in 2010–11 requesting further safety information from developers indicate that a more solid clinical evidence base must be established to gain approval in obesity. This is likely to drive the trend of increasing patient enrollment numbers and trial duration for anti-obesity drugs
Antidiabetic drugs with a weight-negative profile are establishing a place in all phases of the obesity pipeline. Novo Nordisk and Eli Lilly both have glucagon-like peptide-1 agonists (GLP-1s) in development for obesity. The most advanced of which is liraglutide, in Phase III trials for obesity

Your key questions answered
• Datamonitor's updated, comprehensive overview of the obesity pipeline
• Understand how recently issued Complete Response Letters are shaping the obesity pipeline
• Escalating regulatory demands have prevented new drug approvals and will continue to influence developmental strategy and trial design

Buy Now: http://www.reportsnreports.com/reports/83953-rd-trends-obesity-20062011-obesitys-lean-years.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “R&D Trends: Insulin Antidiabetics - The future is analogs” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/29/2011 -- The insulin antidiabetic pipeline can be split between small manufacturers, often targeting reformulations of existing insulin, and major manufacturers pursuing novel insulin analogs. Pipeline products will need to show improvements in the clinical safety/side-effect profile of insulins, as change in delivery method alone will not be enough to gain market share.

Features and benefits
• Comprehensive analysis of the current insulin antidiabetic pipeline including both reformulations of marketed insulins and novel analog products.
• Establish the minimum acceptable and target product profiles necessary for success in the insulins market
• Assess future directions in insulin therapies in diabetes.
• Provide insight into clinical trial design and trends in insulin antidiabetics

Highlights
The insulin pipeline consists of 26 clinical trial candidates, of which 20 are in Phase I or Phase II development. Small manufacturers are developing reformulations of human insulin to improve delivery or pharmacological profile, while major insulin players are focusing entirely on analog insulins and combinations.
Comparator insulins Lantus, NovoRapid, and Novomix are well accepted in the market, but pipeline products can target unmet needs associated with clinical safety and side effects, particularly by reducing hypoglycemia and reducing weight gain.
A key future trend in insulin use is the growing utilization of technology: sophisticated pen injectors are replacing traditional vial and syringe delivery, and the use of insulin pumps to deliver a calibrated dose regime is growing.

Your key questions answered
• Datamonitor's updated, comprehensive overview of the diabetes pipeline.
• Assess the remaining market opportunities and barriers to uptake for novel insulin therapies and formulations.
• Identify clinical trial requirements and trends in insulin antidiabetics.

Buy Now: http://www.reportsnreports.com/reports/83952-rd-trends-insulin-antidiabetics-the-future-is-analogs.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “Epidemiology: Major Orthopedic Surgery – On the rise as the global elderly population continues to grow” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/27/2011 -- In 2010, Datamonitor estimates that there were 5.3 million orthopedic surgeries in the seven major markets. Due to the aging populations in the seven major markets, this number is projected to increase to approximately 6.6 million orthopedic surgeries in 2020.

Features and benefits
• Gain insight to market potential, including a robust 10-year epidemiology forecast of major orthopedic surgeries.
• Understand the key epidemiologic risk factors associated with major orthopedic surgery and how it is related to deep vein thrombosis.

Highlights

Datamonitor's epidemiologists expect to see an increase in the number of major orthopedic surgeries between 2010 and 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). The number of orthopedic surgeries is expected to increase from approximately 5,284,000 surgeries in 2010 to 6,556,000 surgeries in 2020.

In 2010, Datamonitor expects that the number of orthopedic surgeries will differ significantly by age group. In the seven major markets, there will be approximately 106,900 surgeries in those under 15, 579,300 in those between 15 and 44, 1,547,400 in those between 45 and 64, and 3,050,100 surgeries in those over the age of 65.

With the exception of heart-related surgeries, hip replacement surgery is the most common surgery among the elderly. It is the most commonly performed orthopedic surgery overall, despite being almost exclusively limited to those over the age of 50.

Your key questions answered
• What are the most robust sources for major orthopedic surgery data?
• How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
• How do changes in population structure and risk factors affect the trend in the number of major orthopedic surgeries?

Buy Now: http://www.reportsnreports.com/reports/83951-epidemiology-major-orthopedic-surgery-on-the-rise-as-the-globa.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “Epidemiology: Major Abdominal Surgery – A key risk factor for deep vein thrombosis and pulmonary embolism” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) --06/24/2011 -- In 2010, Datamonitor estimates that there were 7.4 million major abdominal surgeries in the seven major markets. This number is not expected to change significantly, growing to 8.1 million surgeries in 2020.

Buy Now: http://www.reportsnreports.com/reports/83940-epidemiology-major-abdominal-surgery-a-key-risk-factor-for-dee.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

Features and benefits

• Gain insight to market potential, including a robust 10-year epidemiology forecast of major abdominal surgeries.

• Understand the key epidemiologic risk factors associated with major abdominal surgery and how it is related to deep vein thrombosis.
Highlights

Datamonitor's epidemiologists expect to see a small increase in the number of major abdominal surgeries between 2010 and 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). The number of abdominal surgeries is expected to increase from around 7,436,000 surgeries in 2010 to 8,109,000 surgeries in 2020.

In 2010, Datamonitor expects that the number of abdominal surgeries will differ significantly by age group. In the seven major markets, there will be approximately 166,400 surgeries in those under 15, 5,125,000 in those between 15 and 44, 1,194,000 in those between 45 and 64, and 950,300 surgeries in those over the age of 65.

The most commonly performed major abdominal surgery is Cesarean section in all seven major markets. It is estimated that Cesarean sections make up approximately one third of all major abdominal surgeries.

Your key questions answered

• What are the most robust sources for major abdominal surgery data?

• How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?

• How do changes in population structure and risk factors affect the trend in number of major abdominal surgeries?

About Us
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/24/2011 -- Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to increase global awareness, standardize patient care, and reduce levels of mortality for sepsis. Negative clinical trial data have dented the commercial performance of Eli Lilly's Xigris, creating an opportunity for improved sepsis therapeutics.

Features and benefits
• Profile and clinical and commercial evaluation of Eli Lilly's Xigris (drotrecogin alfa [activated]).
• Review of unmet needs for sepsis and future challenges and opportunities in sepsis diagnosis and treatment.
• Overview of the Surviving Sepsis Campaign, including an evaluation of its impact on sepsis patient care.

Highlights

Eli Lilly's Xigris is currently the only marketed direct therapy for sepsis. However, its commercial performance has been disappointing, despite its market monopoly, due to negative results from clinical trials conducted post-approval. Upcoming results from the PROWESS-SHOCK trial are likely to be critical to the future success of the drug.

There is a high unmet need for the identification and utilization of sepsis biomarkers that can identify those patients who would most likely benefit from new drugs and monitor patient response to therapies. However, current approaches lack the required predictive capability and reliability to be employed in clinical practice.

The Surviving Sepsis Campaign (SSC) has proved successful in increasing global awareness of sepsis, standardizing patient care, and reducing patient mortality rates. However, the development of the SSC guidelines has been associated with controversy due to links with industry (particularly Eli Lilly).

Your key questions answered

• Understand the commercial and clinical attractiveness of Eli Lilly's Xigris and the key reasons behind its disappointing commercial performance.
• Understand key unmet needs in sepsis and potential future developments in diagnosis and therapy.
• Gain insight into the Surviving Sepsis Campaign and its impact on sepsis management.

Buy Now: http://www.reportsnreports.com/reports/83943-case-study-sepsis-xigris-disappointing-performance-creates-a-.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Datamonitor’s Report “Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/21/2011 -- Although the majority of HIV drug developers already offer most of their antiretrovirals under differential pricing schemes for lower income countries, few can compete with the lower prices of available generics offered through donor-funded programs. Innovative ways must be found that can balance widespread access to newer HIV drugs while still ensuring profits for pharmaceutical companies.

Features and benefits
* Discussion of differential pricing strategies for pharmaceuticals
* Review of differential pricing strategies for HIV antiretrovirals
* Analysis of driving forces behind the need for better differential pricing strategies for antiretrovirals
* Discussion of incentives that could boost differential pricing policies

Highlights
Although differential pricing strategies are being employed in some areas, several obstacles have so far limited a more widespread utilization. Key difficulties include the threat of parallel trade, external reference pricing, decreased buying power in lower income countries, and concerns that preferential prices are not passed on to consumers.

Generics have increasingly driven down the price for antiretrovirals in lower income markets, making it difficult for pharmaceutical companies and their branded products to stay competitive despite using differential pricing strategies

An increasing need for later-stage treatments and stricter enforcement of intellectual property (IP) rights call for improved strategies to enhance access to newer antiretrovirals

Your key questions answered
* Understand why many HIV markets in developing countries are dominated by generics despite differential pricing by innovative drug developers.
* Learn how differential pricing can be a win-win strategy to promote access to drugs while retaining incentives for pharmaceutical companies.
* Understand why better differential pricing strategies will be key in allowing access to newer antiretrovirals.

Buy Now: http://www.reportsnreports.com/reports/83939-case-study-hiv-better-differential-pricing-strategies-are-nee.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights Report “Trends in Health Technology Assessment” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/20/2011 -- The report explores approaches to HTA, profiles HTA organizations in six countries (Australia, Canada, France, Germany, the UK, and the US) and examines how their results are used to inform pricing and reimbursement decisions. The focus is on pharmaceuticals, medical devices, and diagnostics and how the rapidly evolving HTA environment will influence future market access of these technologies.

Features and benefits
• Analyze what evidence is required for HTA evaluations to show that a particular drug/medtech product represents an improvement on current practice.
• Gain an insight into HTA programs & identify common trends in assessment practices and areas where there are differences in processes and procedures.
• Evaluate how P&R policies are influenced by HTA outcomes and what impact HTA advice has on payors and providers, supported by case studies.
• Assess industry's role in providing evidence that meets diverse HTA demands.
• Evaluate how interaction between regulators and payors could pave the way for greater synergies between regulatory and HTA requirements.

Highlights
Clinical and cost effectiveness are assessed for pharmaceuticals in Australia, Canada and the UK, while clinical benefit is the main focus in France and Germany for new drugs. CER is rapidly gaining momentum in the US to inform federal funding decisions, while commercial US payors use clinical and economic evidence in formulary listings.

Patient input is gaining greater significance in HTA, helping to provide a broader perspective of a product's value in the real world setting. By February 2011, 22 drugs had benefited from the new process for patient group input during the Canadian Common Drug Review since it was introduced in May 2010.

From January 2011, the clinical benefit of all new pharmaceuticals launched in Germany must be assessed on the basis on manufacturers' dossiers. The introduction of value-based pricing in the UK in 2014 will require all new brand medicines to demonstrate value, replacing the current system of selective appraisals by NICE.

Your key questions answered
• What factors are used by different HTA bodies to measure the costs and benefits of health technologies?
• How is advice provided by HTA organizations used by different payors?
• How can companies best approach the need to incorporate HTA requirements into their product development plans?
• What are the key challenges of HTA and what efforts are underway to address theses?
• Which organizations are involved in HTA in Australia, Canada, France, Germany, the UK, and the US?

Buy Now: http://www.reportsnreports.com/reports/89007-trends-in-health-technology-assessment.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Business Insights’s Report “The Women’s Health Market Outlook to 2016” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 06/17/2011 -- The Women's Health Market Outlook to 2016 provides comprehensive coverage of the women's health market, a incorporating disease overview and detailed epidemiological analyses of the major indications. This report makes an in-depth assessment of marketed products, R&D pipelines, market share data, sales forecast and the competitive landscape for the major players.

Features and benefits
• Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
• Compare the franchises of the leading companies in global women's health market, and understand how the market share of these companies will change.
• Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
• Identify the challenges confronted by leading players, and learn from their business strategies.
• Forecast of the leading marketed and pipeline products through to 2015.

Highlights
The global women's health market in 2010 was valued at $23.3bn, with a CAGR of 4.2% (2005–10). It is forecasted to reach $32.8bn by 2016 at a CAGR of 5.9% (2010–16).

Hormonal contraceptives was the largest selling drug class in 2010 and is projected to reach $15.2bn by 2016. This class is dominated by generics and branded generic products.

Osteoporosis treatment is the second largest drug class and consists of many blockbuster brands like Fosamax, Actonel, Evista, Bonvivia.

The top 10 brands in the women's health market accounted for 39.5% of total sales in 2010. Seven out of the top 10 brands are forecasted to decline during the forecast period due to impending or expired patents.

Your key questions answered
• What will be the major growth indications and the accompanying growth drivers in the women's health market to 2016?
• Which were the leading players in the women's health market in 2010? Which companies are best positioned to succeed to 2016?
• Which therapeutic categories and products are forecast to have the highest levels of commercial potential over the period 2010-16?
• What is a successful commercial and marketing strategy in the women's health market?
• What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?

Buy Now: http://www.reportsnreports.com/reports/89004-the-womens-health-market-outlook-to-2016.html

Browse All: http://www.reportsnreports.com/market-research/healthcare/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm